Foundation

Alzheimer's Drug Discovery Foundation (ADDF)

Founded in 1998 by co-chairmen Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation (ADDF) is the only charity solely focused on finding drugs for Alzheimer’s.

Subsidy: $50,000-100,000 for epidemiological analyses; up to $3,000,000 for clinical trials

Funding rate: 100%

Deadlines: 1st stage (LOI): 10 July 2020 an 9 October 2020

2nd stage: 7 August 2020 and 6 November 2020

Project duration: Multi-year; potential for follow-on funding

Consortium: Open to researchers, clinicians, and postdoctoral fellows in the U.S. and worldwide working at: academic medical centers and universities or nonprofits. Biotechnology companies that demonstrate a clear need for funding, and existing companies and startups are both eligible. Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones.

Scope: The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

Specifically, the Prevention Beyond the Pipeline program supports:

  • Studies Leveraging the Consortium of Cohorts for Alzheimer’s Prevention Action (CAPA);
  • Comparative Effectiveness Research;
  • Studies of Cognitive Decline and Cognitive Reserve.

 


Alzheimer’s Drug Discovery Foundation (ADDF): Program To Accelerate Clinical Trials (PACT)

Subsidy: up to $3,000,000

Funding rate: 100%

Deadlines: 1st stage (LOI): 10 July 2020 an 9 October 2020
2nd stage: 7 August 2020 and 6 November 2020

Project duration: Multi-year; potential for follow-on funding

Consortium: Open to researchers, clinicians, and postdoctoral fellows in the U.S. and worldwide working at: academic medical centers and universities or nonprofits. Biotechnology companies that demonstrate a clear need for funding, and existing companies and startups are both eligible. Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones.

Scope: The goal of this program is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. This includes novel, repurposed, and repositioned drugs as well as natural products. The ADDF is interested in small molecules and biologics (e.g. antibodies, peptides, gene therapies).

Specifically, the PACT program supports:

  1. Early-stage human clinical trials;
  2. Regulatory studies.

 


Alzheimer’s Drug Discovery Foundation (ADDF): Neuroimaging And CSF Biomarker Development Program

Subsidy: $600,000

Funding rate: 100%

Deadlines: 1st stage (LOI): 10 July 2020 an 9 October 2020
2nd stage: 7 August 2020 and 6 November 2020

Project duration: One year with potential for follow-on funding. Multi-year proposals can be considered.

Consortium: Open to researchers, clinicians, and postdoctoral fellows in the U.S. and worldwide working at: academic medical centers and universities or nonprofits. Biotechnology companies that demonstrate a clear need for funding, and existing companies and startups are both eligible. Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones.

Scope: The aim of this program is to develop biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias.

Specifically, this program focuses on:

  • Developing novel PET ligands for clinical use
  • Supporting novel CSF biomarkers
  • Validating established MRI approaches in larger cohorts

 


Alzheimer’s Drug Discovery Foundation (ADDF): Prevention Beyond The Pipeline

Subsidy: $50,000-100,000 for epidemiological analyses; up to $3,000,000 for clinical trials

Funding rate: 100%

Deadlines: 1st stage (LOI): 10 July 2020 an 9 October 2020

2nd stage: 7 August 2020 and 6 November 2020

Project duration: Multi-year; potential for follow-on funding

Consortium: Open to researchers, clinicians, and postdoctoral fellows in the U.S. and worldwide working at: academic medical centers and universities or nonprofits. Biotechnology companies that demonstrate a clear need for funding, and existing companies and startups are both eligible. Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones.

Scope: The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

Specifically, the Prevention Beyond the Pipeline program supports:

  • Studies Leveraging the Consortium of Cohorts for Alzheimer’s Prevention Action (CAPA);
  • Comparative Effectiveness Research;
  • Studies of Cognitive Decline and Cognitive Reserve.

More Foundations

 


About Alzheimer’s Drug Discovery Foundation (ADDF)

The ADDF focuses on translating the knowledge they have gained about the causes of Alzheimer’s disease into drugs to conquer it. They support an underfunded area—preclinical drug discovery and early-stage clinical trials of potential drug targets—that is often called the “valley of death” because it’s where good ideas go to die. These projects hold great promise, but also great risk.

And most are not far enough along in the drug development pipeline to attract financial support from the pharmaceutical industry, federal funders, or other major partners. By assuming the risk and bridging this critical gap in funding, the ADDF enables leading scientists to pursue pioneering ideas to cure Alzheimer’s disease that would otherwise go unexplored.

Visit the ADDF website for more information

 


Get funding, make impact

Whether you’re an academic or entrepreneur, we craft the roadmap you need to take on the challenges present in finding funding and reaching your market. With over 10 years of experience, we are your gateway to European funding, and beyond.

  • Fund. What if funding wasn’t a barrier to innovation? We guide you through the way of finding and obtaining funds.
  • Grow. What if your journey was clear? Get the best support for your grant journey.
  • Manage. What if you only had to focus on R&D? We provide the support you need to get your innovation on the market.

More about our consulting services

Newsletter

A must-have if you’re interested in getting your business to the next level